Welcome to our dedicated page for Aurinia Pharmaceuticals news (Ticker: AUPH), a resource for investors and traders seeking the latest updates and insights on Aurinia Pharmaceuticals stock.
Aurinia Pharmaceuticals Inc (symbol: AUPH) is a cutting-edge biopharmaceutical company headquartered at 5120-75 street, Edmonton, Canada. Specializing in the treatment of serious diseases with high unmet medical need, Aurinia is committed to providing innovative therapeutic solutions to patients worldwide. The company's flagship product, LUPKYNIS (voclosporin), is an investigational drug designed for the treatment of lupus nephritis (LN), a severe renal complication of lupus. This groundbreaking treatment underscores Aurinia's focus on developing life-changing medications.
In recent years, Aurinia Pharmaceuticals has made significant strides in its research and development efforts, particularly in the United States, where it derives the majority of its revenue. The company has forged strategic partnerships with leading healthcare organizations and continues to explore new avenues for growth and innovation.
Financially, Aurinia has demonstrated strong performance, with consistent revenue growth driven by its robust pipeline of investigational drugs. The company's commitment to advancing its clinical programs and securing regulatory approvals positions it well for sustained success in the biopharmaceutical industry.
With a dedicated team of experts and a clear vision for the future, Aurinia Pharmaceuticals is poised to make a lasting impact on global healthcare. Investors and stakeholders can stay updated on the latest developments, financial results, and strategic initiatives through the company's regular news updates and investor relations communications.
Aurinia Pharmaceuticals (NASDAQ: AUPH) has filed a supplement to its Proxy Statement dated June 3, 2024. The supplement aims to reduce the proposed increase in shares reserved under the Equity Incentive Plan from 11,375,000 to 8,500,000. The revised total increase of 8,500,000 Plan Shares now represents 22.7% of total shares outstanding as of April 30, 2024. The supplement amends the Proxy Statement to decrease the number of Plan Shares from 35,190,115 to 32,315,115. Shareholders are encouraged to read the supplement alongside the Proxy Statement. The document is available on Aurinia's website and on EDGAR and SEDAR+.
Lucien Selce, who owns 2.2% of Aurinia Pharmaceuticals (NASDAQ: AUPH), has urged shareholders to withhold support for CEO Peter Greenleaf and the current Board of Directors in the upcoming AGM on June 14, 2024. Selce accuses the Board of manipulating AGM dates to benefit from stock-based compensation and depriving certain shareholders of their voting rights. A leading proxy advisory firm, ISS, has also recommended withholding support for three directors and voting against proposed executive compensation. Selce highlights the stock's decline from $10.71 to $5.42 and suggests a new Board and CEO to rejuvenate Aurinia's performance and governance.
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced its participation in the 2024 Jefferies Global Healthcare Conference in New York, scheduled from June 4-6, 2024.
The company's management will engage in one-on-one meetings with investors and deliver a presentation on June 5 from 8:00 to 8:25 AM Eastern Time.
A live webcast of the session will be accessible via the Investor section of Aurinia's website.
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced the cost-effectiveness of LUPKYNIS® (voclosporin) for treating lupus nephritis (LN) at the National Kidney Foundation Spring Clinical Meeting 2024. The updated analysis, consistent with a 2021 assessment, utilized the ICER AnalyticsTM LN model and found LUPKYNIS to be below the $150,000 willingness-to-pay threshold, costing $88,076 per QALY and $77,643 per evLYG for adults with active LN. For Black, Hispanic, and Latino patients, costs were $77,436 per QALY and $67,828 per evLYG. Additional data from the AURORA clinical program and the Enlight-LN registry highlighted the drug's sustained efficacy and reduced steroid use over three years. A propensity analysis indicated superior proteinuria reduction and decreased exposure to toxicities versus high-dose glucocorticoid regimens.
Aurinia Pharmaceuticals Inc. presented data at the Congress of Clinical Rheumatology East 2024, reinforcing the safety and efficacy of LUPKYNIS in treating lupus nephritis. The studies showed that LUPKYNIS in combination with standard care reduced toxicities and proteinuria compared to conventional treatments. Black patients experienced improved outcomes with LUPKYNIS.
A shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has urged the Board of Directors to take action to enhance shareholder value. The shareholder, Lucien Selce, expressed concerns about the Company's current strategy, Board composition, and market penetration. He outlined the need for restructuring the Board, setting clear objectives for market penetration, and developing strategic partnerships to improve performance and shareholder value.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will attend the 2024 RBC Capital Markets Global Healthcare Conference in New York from May 14-15, 2024. Management will host one-on-one meetings with investors and participate in a fireside chat. A live webcast of the session will be available on the company's website.
Aurinia Pharmaceuticals Inc. reported $50.3 million in total net revenue and $48.1 million in net product revenue for the first quarter of 2024, with a year-over-year growth of approximately 46% and 40% respectively. The company achieved significant milestones like FDA approval for LUPKYNIS and plans to reach positive free cash flows in Q2 2024. The 2024 net product revenue guidance is $200 to $220 million. Financially, total net revenue increased, operating expenses decreased, and the company maintained a strong liquidity position.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) reaffirms its commitment to raising awareness about lupus nephritis (LN) during Lupus Awareness Month. The company is engaging in various education initiatives to improve understanding, screening, and management of LN. Through partnerships and advocacy efforts, Aurinia aims to eliminate barriers to access, promote equity, and enhance health outcomes for individuals affected by LN.
The FDA has approved an updated label for LUPKYNIS, a drug by Aurinia Pharmaceuticals (NASDAQ: AUPH), including long-term data from the AURORA Clinical Program, showing sustained complete renal response through three years. The label now indicates that monthly kidney function assessment is no longer required after the first year of treatment. The safety profile of LUPKYNIS remains unchanged and aligns with the AURORA clinical program's findings.
FAQ
What is the current stock price of Aurinia Pharmaceuticals (AUPH)?
What is the market cap of Aurinia Pharmaceuticals (AUPH)?
What does Aurinia Pharmaceuticals Inc. specialize in?
Where is Aurinia Pharmaceuticals Inc. located?
What is LUPKYNIS (voclosporin)?
Where does Aurinia Pharmaceuticals derive most of its revenue?
What recent achievements has Aurinia Pharmaceuticals accomplished?
How can investors stay updated on Aurinia Pharmaceuticals' latest news?
What is the significance of LUPKYNIS for Aurinia Pharmaceuticals?
What type of diseases does Aurinia Pharmaceuticals focus on?
Has Aurinia Pharmaceuticals formed any partnerships?
What is the outlook for Aurinia Pharmaceuticals’ future?
